纳米杀毒剂将在刚果开始第二阶段的麻疹治疗试验. NanoViricides to start Phase II trial for monkeypox treatment in Congo.

刚果民主共和国即将开始对NV-387进行第二阶段临床试验, 这是一种潜在的治疗方法. 在刚果这个病毒流行的地方, A Phase II clinical trial for NV-387, a potential monkeypox treatment, is set to begin soon in the Democratic Republic of Congo, where the virus is endemic. 美国生物技术公司NanoViricides申请了孤儿药物指定,以加快开发速度,因为现有的疫苗和TPOXX等药物存在局限性,而更严重的Clade I病例在美国正在增加. The U.S. biotech company NanoViricides has applied for Orphan Drug Designation to expedite development, as existing vaccines and drugs like TPOXX have limitations, and U.S. cases of the more severe Clade I are rising.